Question

Which of the following recommendations would be most appropriate when discussing a change in therapy from Exjade (deferasirox) to Jadenu (deferasirox) with a healthcare provider?

1) There is no need to monitor renal function with Jadenu
2) The Jadenu dose should be started at a dosage 30
3) Dosing is based on equivalent mg/kg dosing parameters
4) d. Increase the Exjade dose when switching to Jadenu

Answer 1

The most appropriate recommendation when switching from Exjade to Jadenu is that dosing is based on equivalent mg/kg parameters, with close monitoring of renal function as it remains an important safety measure.

Step-by-step explanation:

When discussing a change in therapy from Exjade (deferasirox) to Jadenu (deferasirox), the most appropriate recommendation to discuss with a healthcare provider would likely be that dosing is based on equivalent mg/kg dosing parameters. Although Exjade and Jadenu contain the same active ingredient, deferasirox, they have different formulations that may require different dosing. Monitoring of renal function is still necessary when switching to Jadenu, as it is part of the safety monitoring for patients on deferasirox treatments. It is incorrect to start Jadenu at a dosage reduced by 30% or to increase the Exjade dose when transitioning to Jadenu without clinical justification and a provider's guidance.